Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics IncfiledCriticalBioxcel Therapeutics Inc
Publication of AR117290A1publicationCriticalpatent/AR117290A1/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Un régimen para tratar a un sujeto que padece cáncer de próstata mediante la administración de Talabostat, o una sal farmacéuticamente aceptable del mismo, y Pembrolizumab.
ARP190103600A2018-12-102019-12-10Enfoque de tratamiento de cáncer mediante inmunomodulación
AR117290A1
(es)